GTR Home > Tests > Search results - C1866552[DISCUI]

Apply filters

Showing tests for all 2448 conditions

Compare labs

Your search term can be found in tests with a total of 2448 conditions. Only 1000 conditions are displayed in this filter box. Please type the name of the condition in the search box in this filter to find the specific condition. You can use the filters below to narrow down your results.
If the name of the condition you typed is not present, please try another query or search using the All GTR tab.

  • Hide states

GTR test search results for C1866552[DISCUI]

C Clinical test, R Research test

Showing 1 to 20 of 23 tests for 2448 conditions in 12 labs

CHereditary Pheochromocytoma and Paraganglioma Panel

Lab: Genetic Services Laboratory University of Chicago Chicago, Illinois, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (10)
Total targets (14)

CTruGenome Predisposition Screen (Whole Genome Sequencing)

Lab: Illumina Clinical Services Laboratory Illumina San Diego, California, United States
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (1541)
Total targets (1578)

CSDHAF2 Comprehensive - Sequence & Deletion/Duplication Analysis

Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

CSDHAF2 Sequence Analysis

Test targets
Methods
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

CHereditary Paraganglioma-Pheochromocytoma Syndrome NextGen Sequencing Panel

Lab: PreventionGenetics Marshfield, Wisconsin, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis
Total conditions (11)
Total targets (11)

CHereditary Paraganglioma-Pheochromocytoma Syndrome via the SDHAF2 Gene

Lab: PreventionGenetics Marshfield, Wisconsin, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

CHereditary Paraganglioma-Pheochromocytoma Syndrome Sanger Sequencing Panel

Lab: PreventionGenetics Marshfield, Wisconsin, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (9)
Total targets (7)

CNuclearMitome Test

Lab: Transgenomic New Haven, Connecticut, United States
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (386)
Total targets (434)

CepiSEEK® Comprehensive Sequence Analysis for Epilepsy and Seizure Disorders (489 genes)

Lab: Courtagen Diagnostics Laboratory Courtagen Life Sciences Woburn, Massachusetts, United States
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (641)
Total targets (439)

CParagangliomas 2 (sequence analysis of SDHAF2 gene)

Lab: CGC Genetics Porto, Porto, Portugal
Test targets
Methods
  • C Sequence analysis of the entire coding region

CCancer Predisposition

Lab: Asper Biotech Asper Biotech Ltd. Tartu, Tartumaa, Estonia
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (134)
Total targets (100)

CSDHAF2

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

CHereditary Cancer Syndrome: Sequencing Panel

Lab: Emory Genetics Laboratory Emory University Decatur, Georgia, United States
Conditions
Test targets
Methods
  • C Sequence analysis of the entire coding region
Total conditions (107)
Total targets (46)

CNuclear-Mito NGS Panel

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (601)
Total targets (504)

CKidney Renal Cancer NGS Panel

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (83)
Total targets (19)

CParaganglioma-Pheochromocytomas NGS Panel

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (34)
Total targets (12)

CHereditary Cancer NGS Panel

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Conditions
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (256)
Total targets (112)

CEpilepsy NGS Panel

Lab: Fulgent Clinical Diagnostics Lab Fulgent Diagnostics Temple City, California, United States
Test targets
Methods
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
Total conditions (598)
Total targets (343)

Showing 1 to 20 of 23 tests for 2448 conditions in 12 labs

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.